Recurrent bone marrow aplasia secondary to nilotinib in a patient with chronic myeloid leukemia: A case report
Authors:
- 7 March 2012
- journal article
- research article
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 18 (4) , 440-444
Abstract
Nilotinib is a potent tyrosine kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL), which has been approved as front-line therapy for newly diagnosed chronic myeloid leukemia in chronic phase and as second-line therapy after imatinib failure in chronic or accelerated phase chronic myeloid leukemia. Tyrosine kinase inhibitors have been associated with myelosuppression and grade 3 or grade 4 cytopenias are not uncommon in chronic myeloid leukemia patients treated with these drugs. There are a few reports of imatinib-associated bone marrow aplasia, but to our knowledge only one reported case of bone marrow aplasia associated with nilotinib. Herein, we report a 49-year-old male patient with chronic phase chronic myeloid leukemia, who developed severe bone marrow aplasia due to nilotinib. Possible mechanisms for this significant adverse drug reaction are discussed along with a review of literature.Keywords
This publication has 29 references indexed in Scilit:
- Nilotinib‐induced bone marrow aplasiaEuropean Journal of Haematology, 2009
- Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failureCancer, 2009
- Gelatinous Transformation of Bone Marrow in Chronic Myeloid Leukemia during Treatment with Imatinib Mesylate: A Disease or a Drug Effect?Acta Haematologica, 2008
- Bone marrow aplasia—a rare complication of imatinib therapy in CML patientsAmerican Journal of Hematology, 2007
- Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 2006
- Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemiaLeukemia Research, 2005
- Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemiaLeukemia & Lymphoma, 2005
- Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemiaSeminars in Hematology, 2003
- STI571 (Imatinib Mesylate) Reduces Bone Marrow Cellularity and Normalizes Morphologic Features Irrespective of Cytogenetic ResponseAmerican Journal of Clinical Pathology, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002